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Abstract: Clinical trials in attention-deficit/hyperactivity disorder (ADHD) have typically measured
outcome using clinician ratings on the Attention-Deficit/Hyperactivity Disorder Rating Scale, Fourth
Edition (ADHD-RS-IV) and the Clinical Global Impression-Improvement (CGI-I) scale. Remission has
been defined as an endpoint score of less than or equal to 18 on the ADHD-RS-IV (or a mean score
of 1). Responders have been defined as patients who achieve a CGI-I score of much or very much
improved (1 or 2). There is a lack of agreement in the literature on what percent change in symptoms
on the ADHD-RS-IV should be used to define improvement or remission. This study uses data
from a clinical trial of a methylphenidate extended release (MPH-MLR; Aptensio XR® ) phase III
clinical trial to attempt to determine the percent change of symptoms that best corresponds with
improvement and remission. Symptom remission at endpoint (ADHD-RS-IV total score ≤18) was
most closely aligned with a ≥46% reduction in ADHD-RS-IV total score. Clinical improvement
was most closely aligned with a ≥40% reduction in ADHD-RS-IV total score. The three different
measures of outcome were strongly aligned during double blind and open label treatment, and were
independent of subtype status. Our data suggest that at least 40% improvement in symptoms is
needed to achieve a robust response at endpoint.
Keywords: attention deficit/hyperactivity disorder; central nervous system stimulants; methylphenidate;
remission; response

1. Introduction
Clinical trials of medication and psychological treatments for attention-deficit/hyperactivity
disorder (ADHD) have looked at outcome in terms of symptom change from baseline, overall clinical
improvement, and final symptom endpoint. Each of these provides a slightly different perspective on
treatment response. For example, percent decrease in symptom scores reflects change from baseline.
Clinical global impression of improvement also reflects change from baseline, but goes beyond core
symptoms. Remission reflects patient achievement of a final outcome that would be considered
“normalization”. Endpoint scores are distinct from change scores in that if someone starts treatment
very ill (i.e., a symptom score of 54) and has a 50% drop in symptoms, they may still be moderately
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symptomatic. Past trials have used arbitrary cutoffs for percent change in symptoms ranging from
25% to 40%.
The importance of differentiating response in terms of improvement vs. remission first became
apparent in a post hoc reanalysis of the Multimodal Treatment Study of Children with ADHD
study [1]. Differences between the treatment arms that were not obvious looking solely at improvement
were much more apparent when considering remission or normalization [2]. Biederman et al. [3]
further defined three standards of outcome that can be applied to age-dependent decline in ADHD:
syndromatic (less than full syndrome), symptomatic (less than subthreshold diagnosis), and functional
(full recovery) remission. This study was unique; the authors compensated for the impact of
subtype on final score by looking at three symptom clusters independently: attention, hyperactivity,
and impulsivity. They defined “syndromatic remission” as failing to meet the full diagnostic criteria
for ADHD, which meant the patient still had symptoms but no longer met diagnostic criteria.
“Symptomatic remission” required that the patient have fewer than the number of symptoms required
for a subthreshold diagnosis. The most robust definition of remission was “functional remission”,
which required that the patient have fewer than 36% of the symptoms of ADHD and no impairment
(score on the Global Assessment of Functioning Scale higher than 60). Few clinical trials have followed
this methodology in distinguishing not just symptom improvement from symptom remission, but also
in looking at remission as requiring both normalization of symptoms and functioning. Even more
important in this study was the use of a methodology that looked at attention, hyperactivity and
impulsivity independently [3]. In a patient with combined type ADHD, all 18 items are equally
relevant; however, in a patient with only attention problems, the total score underestimates severity,
because only the 9 items of attention are relevant.
Throughout the various versions of the Diagnostic and Statistical Manual of Mental Disorders
(DSM), rating scales for ADHD have scored the 18 DSM symptoms of ADHD on a 4-point Likert
scale. The anchor points for measurement of symptoms have been either based on frequency (not at
all = 0, just a little = 1, pretty much = 2, or very much = 3, such as the Swanson, Nolan, and Pelham
Questionnaire [SNAP] [2]) or severity (never = 0, occasionally = 1, often = 2, or very often = 3, such as
the Vanderbilt [4]). We are not aware of any studies comparing the relative validity or relationship
between using frequency or severity ratings. A consensus standard in the field, however, has been
to consider any rating of 2 or 3 as symptomatic, whether this is defined by severity or frequency.
A symptom rated 2 or 3 is considered to be present, and whether or not a patient meets the criteria
for syndromatic remission is then determined by whether they meet the 6/9 criteria for attention or
hyperactive/disruptive symptoms (or 5/9 if older than 17 years).
The Attention-Deficit/Hyperactivity Disorder Rating Scale, Fourth Edition (ADHD-RS-IV) rates
each of the 18 DSM, Fourth Edition (DSM-IV) ADHD symptoms as never or rarely = 0, sometimes =
1, often = 2, and very often = 3 [5]. The DSM-IV defines mild ADHD as few symptoms in excess of
those required for diagnosis and mild impairment; and severe ADHD as many symptoms in excess of
those required to make the diagnosis, symptoms that are very severe, or marked impairment. It should
be noted, however, that normative studies have defined T scores that show considerable variation
between ages and genders, although T scores are rarely used in outcome analysis. An ADHD-RS-IV
total score ≤18 (i.e., mild or less on average) has been used as a cut point for ADHD symptomatic
remission [6].
A wide range of definitions and assessment tools have been used to try to define treatment
response and disease remission; medication trials in children have used a variety of endpoints to
describe these terms [7–11]. This is the first study we are aware of that attempts to look empirically
at what percent change in symptoms is best anchored to global improvement and remission. In this
secondary analysis, data from a large phase III methylphenidate multi-layer release (MPH-MLR) trial
(ClinicalTrials.gov identifier NCT01239030) were utilized to investigate various measures of clinical
response and symptomatic remission associated with MPH-MLR treatment in children and adolescents
with ADHD.
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MLR-MPH is a once-daily beaded formulation composed of an immediate-release layer and a
delayed-release layer. Administration results in a rapid rise in plasma levels after oral administration
with an onset of action within 1 h and a duration of action of 12 h. MLR-MPH has a bimodal release
such that the outer layer is equal to that of immediate-release MPH with initial rapid dissolution and
absorption of 40% of the dose, followed by an evenly maintained release of MPH through the day
from the second layer.
The relationship between percent change in the ADHD-RS-IV total score versus a predefined
symptom threshold cutoff of ADHD-RS-IV total score ≤18 (symptomatic remission) versus a Clinical
Global Impression (CGI)-Improvement (CGI-I) score of much or very much improved was explored to
further understand the relationship and agreement between these outcomes. Furthermore, whether
these relationships are similar for the combined versus inattentive ADHD subtypes will be explored.
There were not enough patients with hyperactive/impulsive subtype to power inclusion of this group.
2. Materials and Methods
2.1. Trial Design
The design and primary results of this phase III, randomized, double-blind, placebo-controlled,
parallel, fixed-dose study of MPH-MLR safety and efficacy have been previously published [12].
Briefly, the study included 4 phases: screening (≤28 days), double-blind fixed-dose phase (1 week),
open-label dose-optimization phase (11 weeks), and a follow-up call. Children and adolescents (male
and female) aged 6–18 years at the time of consent with an ADHD diagnosis of all subtypes (except “not
otherwise specified”) as defined in the DSM-IV, Text Revision were included. During the double-blind
fixed-dose phase, patients were randomized (1:1:1:1:1) to receive MPH-MLR 10, 15, 20, or 40 mg,
or placebo. During the open-label dose-optimization phase, treatment was initiated with a once-daily
MPH-MLR 10 mg dose, unless the investigator determined, from earlier experience, that a higher
dose would be needed, and titrated (up or down) at weekly intervals until dosing was optimized.
The dose was increased until there was no further improvement in the ADHD-RS or CGI or further
increases were limited by side effects. There was an option to go beyond 40 mg to 60 mg if required.
At completion of the open-label dose-optimization phase, patients were offered the opportunity to
continue to receive MPH-MLR for up to 21 months (open-label compassionate use extension) for those
patients requiring ongoing treatment. The length of the open-label compassionate use extension was
modified during the study, and thus not all patients had the full 21 months available to them.
This study was conducted in compliance with the Good Clinical Practice guidelines of
the International Conference on Harmonization of Technical Requirements for Registration of
Pharmaceuticals for Human Use, the US Code of Federal Regulations that relate to clinical trial
conduct, and the principles of the Declaration of Helsinki. An institutional review board for each of
the 16 study sites reviewed and approved the protocol, amendments, and informed consent.
2.2. Measures
2.2.1. Attention-Deficit/Hyperactivity Disorder (ADHD) Symptom Change
ADHD symptoms were measured using the ADHD-RS-IV [4]. The ADHD-RS-IV has acceptable
psychometric properties including inter-rater reliability, test-retest reliability, internal consistency, factor
structure, convergent and divergent validity, discriminant validity, and responsiveness. The scale was
administered by trained clinicians at baseline (start of the double-blind fixed-dose phase [visit 2]),
at the end of the double-blind fixed-dose phase on day 7 (visit 3), and on days 14 (visit 4), 21 (visit 5),
28 (visit 6), 56 (visit 7), and 84 (visit 8), and throughout the open-label compassionate use extension
(visits 15–18; visits 15–18 were nominally every 2 months, and few patients were enrolled after visit 18,
although some continued for up to 21 months). Each item on the ADHD-RS-IV is reflective of 1 of the
18 ADHD symptoms included in the DSM-IV.
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2.2.2. Clinical Global Impression (CGI)
The CGI is a measure that is used as a standard in clinical trials to reflect the clinician’s initial
global impression of patient severity (CGI-S) at baseline and improvement with treatment (CGI-I).
The CGI-S [13] is a 7-point scale that requires the clinician to rate the severity of the patient’s illness
at the time of assessment, relative to the clinician’s past experience with patients who have the same
diagnosis. Possible ratings range from normal to among the most severely ill patients. The CGI-I is
a 7-point scale that requires the clinician to assess how much of the patient’s illness has improved
or worsened relative to a baseline state at the beginning of the intervention and rated as: very much
improved, much improved, minimally improved, no change, minimally worse, much worse or very
much worse. By convention, the CGI-I is analyzed as a categorical variable reporting the percent of
patients at endpoint who are rated as much or very much improved. In this trial the CGI-I score was
rated by the clinician based on all data at day 7 (end of the double-blind fixed-dose phase); and on
days 14, 21, 28, 56, and 84; and throughout the open-label compassionate use extension.
2.2.3. Remission
Remission has been variously defined as a mean score of ≤1 of all 18 items [2] on the ADHD-RS-IV
or as a final endpoint score of ≤18. For the purposes of this study, remission was defined as a final
score of ≤18 [14], which is the definition of remission accepted in the literature.
2.3. Analyses
This post hoc analysis determined the percentage reduction in ADHD-RS-IV total score that
best aligned with CGI-I score ≤2 (very much or much improved). For each visit after baseline,
the percentage reduction in ADHD-RS-IV total score was calculated as:
100 × (baseline visit score − this visit score)/baseline visit score
The percentage reduction that best aligned with CGI-I score ≤2 was determined as follows.
For each visit, for each percentage reduction (ranging from 30–50%), the percentage of patients with at
least the given reduction was compared with the percentage of patients with CGI-I score ≤2, and the
percentage of patients with agreement between the 2 measures was calculated. The range was derived
from the consensus that 30% has been described as the lower limit defining improvement, and 50% as
the upper limit defining remission. For example, perfect agreement for a reduction of ≥30% and CGI-I
score ≤2 would occur if all patients with a reduction of ≥30% had CGI-I score ≤2 and all patients
with a reduction of <30% had CGI-I score >2. The 95% confidence interval (CI) for the percentage
of patients with agreement was calculated, and McNemar’s exact test was used to compare the
percentage of patients with at least the given reduction to the percentage of patients with CGI-I score
≤2. The percentage reduction that best aligned was the one with the greatest percentage of patients
with agreement. Fisher’s exact test was used to compare the combined and inattentive subtypes using
the percentage of patients with agreement of combined and inattentive ADHD subtypes.
This post hoc analysis also determined the percentage reduction in ADHD-RS-IV total score that
best aligned with ADHD-RS-IV total score ≤18 with a similar method.
All calculations utilized SAS 9.4 (SAS Institute Inc., Cary, NC, USA).
3. Results
3.1. Response to Treatment
At least 1 dose of the study drug was taken by 230 enrolled patients (safety population),
221 patients were included in the evaluable population, and 200 patients completed the open-label
dose-optimization phase. Two-thirds of the sample were stimulant naïve, and one-third of the sample
(75/221) had a medication washout. The option to enter the open-label compassionate use extension
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Table 1. Baseline demographic and clinical characteristics (safety population, n = 230).
Table 1. Baseline demographic and clinical characteristics (safety population, n = 230).
Characteristic, n (%)

Characteristic, n (%)

MPH-MLR
MPH-MLR
(n = 183)

(n = 183)
Age group, y
6–8
49 (26.8) 49 (26.8)
6–8
9–11
56 (30.6) 56 (30.6)
9–11
12–14
55 (30.1)
12–14
55 (30.1)
15–18
23 (12.6)
15–18
Female
59 (32.2) 23 (12.6)
White
125 (68.3) 59 (32.2)
Female
White
125 (68.3)
ADHD diagnosis subtype
ADHD
diagnosis
subtype
Combined
111 (60.7)
Combined
Predominantly inattentive
62 (33.9) 111 (60.7)
Predominantly inattentive
62 (33.9)
Predominantly
5 (2.7)
hyperactive/impulsive
Predominantly hyperactive/impulsive
5 (2.7)
Not reported
5 (2.7)
Not reported
5 (2.7)
Age group, y

Placebo

Placebo
(n = 47)
(n = 47)

(23.4)
1111
(23.4)
20
(42.6)
20 (42.6)
8 (17.0)
8 (17.0)
8 (17.0)
8 17
(17.0)
(36.2)
(70.2)
1733
(36.2)
33 (70.2)
29 (61.7)

2913
(61.7)
(27.7)
13 (27.7)
1 (2.1)
1 (2.1)
4 (8.5)
4 (8.5)

ADHD:
attention-deficit/hyperactivity disorder;
disorder; MPH-MLR:
extended
release.
ADHD:
attention-deficit/hyperactivity
MPH-MLR:methylphenidate
methylphenidate
extended
release.
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Figure 1. Percentage of patients achieving clinical response or symptomatic remission after
Figure 1. Percentage of patients achieving clinical response or symptomatic remission after 1 week of
1 week of double-blind fixed-dose methylphenidate extended-release treatment. ADHD-RS-IV:
double-blind fixed-dose methylphenidate extended-release treatment. ADHD-RS-IV: AttentionAttention-Deficit/Hyperactivity Disorder Rating Scale, Fourth Edition; CGI-I: Clinical
Deficit/Hyperactivity Disorder Rating Scale, Fourth Edition; CGI-I: Clinical Global ImpressionsGlobal Impressions-Improvement.
Improvement.
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not statistically
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was not statistically different for these 2 measures (McNemar’s exact test, p = 0.56). There was
between these measures in 88% of patients (195/221; 95% CI, 83–92%). The percentage of patients with
agreement between these measures in 88% of patients (195/221; 95% CI, 83–92%). The percentage of
agreement
was similar for combined (120/134 [90%]) and inattentive (61/72 [85%]) subtypes (Fisher’s
patients with agreement was similar for combined (120/134 [90%]) and inattentive (61/72 [85%])
exactsubtypes
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Clinical
response,
defined
as a CGI-I score ≤2, was achieved in 92% (183/200) of patients. Symptomatic remission (ADHD-RS-IV
total score ≤18) was achieved in 75% of patients. Throughout the open-label dose-optimization
phase, CGI-I score ≤2 remained closely aligned, with a 40% reduction in ADHD-RS-IV total
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as a CGI-I score ≤2, was achieved in 92% (183/200) of patients. Symptomatic remission (ADHD-RSIV total score ≤18) was achieved in 75% of patients. Throughout the open-label dose-optimization
phase, CGI-I score ≤2 remained closely aligned, with a 40% reduction in ADHD-RS-IV total score
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Figure 4. Improvement in different attention-deficit/hyperactivity disorder measures with open-label
Figure 4. Improvement in different attention-deficit/hyperactivity disorder measures with open-label
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3.5. Relationships During Open-Label Compassionate Use Extension
Throughout the open-label compassionate use extension, overall response and remission rates
were maintained by the majority of patients. There was sustained alignment between symptomatic
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3.5. Relationships During Open-Label Compassionate Use Extension
Throughout the open-label compassionate use extension, overall response and remission rates
were maintained by the majority of patients. There was sustained alignment between symptomatic
response (≥30% symptom improvement in ADHD-RS-IV total scores) and the clinician’s global
assessment of being much or very much improved, with CGI-I scores ≤2 (Figures 3 and 4).
Symptom improvement of ≥46% remained in agreement with symptomatic remission.
4. Discussions
Throughout various phases of the study, the percentage of patients achieving 40% symptom
improvement was in best agreement with achieving CGI-I response. A 46% symptom improvement
was in best agreement with symptom remission. While ~90% of patients in this trial were able to
achieve some symptom improvement (defined as ≥30% improvement in ADHD-RS-IV total score),
it should be noted that only ~75% were able to achieve symptom remission. This pattern of response,
in which most patients achieve improvement and a majority achieve remission, is consistent with other
stimulant trials [15–17].
These data help to clarify our understanding of the relationship between symptom change, clinical
improvement and symptom remission. Although each of these outcomes describes a slightly different
way of looking at response, this study demonstrates that these outcomes are closely aligned. Our results
emphasize the importance of targeting remission rather than simply response as the standard of care.
Most important, this study provides empirical criteria to define the percent of change that should be
considered as the convention for response in clinical trials. Previous definitions of symptom response
that used 30% change as an acceptable measure of outcome probably were generous in identifying
whether patients showed some degree of palliation with intervention, but may have contributed to
clinicians failing to treat to optimization. Further research needs to look at how these definitions of
symptom response correlate with actual functional improvement and remission.
Importantly, analyses of data from this pivotal trial demonstrated that the agreement of CGI-I score
≤2 and a 40% reduction in ADHD-RS-IV total score held for patients with combined and predominantly
inattentive subtypes. The agreement between and ADHD-RS-IV total score ≤18 and a ≥46% reduction in
ADHD-RS-IV total score also held for both of these subtypes. This likely reflects the fact that the majority
of patients in the trial had challenges in both domains. Clinicians should be cautious in looking only at
total scores for 18 items, when looking at outcome in individuals where problems are largely limited to
either attention or hyperactive/impulsive difficulty. For example, if a patient has a mean score of 2 for
9 symptoms of just hyperactive or just inattentive symptoms, they would be clinically moderately ill,
but would still meet the criteria for “remission” defined as an endpoint score of 18.
A robust standard for fine tuning a high standard of treatment response, as per the methodology
used by Swanson in comparing treatments in the Multimodal Treatment of ADHD (MTA) study [2],
would determine the number of patients with full symptomatic and functional response. While this
might reveal cross-treatment differences that are not otherwise apparent, even more important is that
setting the bar to this standard would encourage clinicians to look at optimizing dose, and augmenting
medication with environmental and psychosocial interventions to treat residual difficulties which
would further improve the lives of patients with ADHD.
This study has several limitations. This is an exploratory post hoc analysis using data from a
pivotal trial that included a representative ADHD patient population and used a phase III, double-blind,
parallel, fixed-dose, randomized design, followed by open label. Given the conventional methodology
of the trial, this is a reasonable sample with which to examine the relationship between outcome and
measures. Nonetheless, the results are representative of the particulars of this design and patient
population and need to be replicated in other types of trial design, populations, and types of treatment
intervention. Two-thirds of the sample were stimulant naïve, and it is unclear how this may have
impacted patient perception of symptoms. Although we had a full range of responses, partly because
the double-blind period was short and dose was randomized rather than optimized, the high agreement
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between outcomes we obtained in open-label follow-up may reflect a limitation of the high rate of
response in open label follow ups, given that non-responders would not typically stay in the study.
It should also be noted that all of these measures are completed by clinicians and have a certain
degree of overlap. For example, the clinician is aware of the ADHD-RS rating when completing the
CGI, so our results do not reflect truly independent measures or interrater reliability. No special
training was done to standardize clinician ratings, but again this is not atypical of clinical trials conduct.
Nonetheless, this is how these outcomes are completed in clinical trials in ADHD and reflect real world
practice. Further research on standardizing appropriate clinical trial outcomes in ADHD, avoiding
redundancy between scale outcomes that overlap, and empirical definition of response vs. remission
are needed. This research would require receiver operating characteristics to determine the most
sensitive cut points, and logistic regression analysis to compare across measures and outcomes.
Other limitations of this study reflect limitations of current methodology for measuring outcome
in ADHD clinical trials in general. First, although by definition remission should be considered as per
the work of Biederman et al. [3] as both symptom and functional remission, the definition used here
refers only to symptoms.
5. Conclusions
This is the first study we are aware of that examines the relationship between different definitions of
symptom improvement and symptom remission and specifies empirically the percent change in symptoms
associated with each of these outcome targets. High rates of clinical response to stimulant treatment in
patients with ADHD have been well documented. This study identifies an empirical definition of percent
symptom change that can be used as a standard to identify success in achieving optimal outcomes, and a
way of differentiating small differences across trials that otherwise might not be apparent.
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